Brookline Capital Acquisition Corp.
BCAC
NASDAQ Capital Market22.71
USD
+12.72
- -
CIK
0001814140
ISIN
US11374E1047
Return %
Stock
S&P500
1Y
126.42
26.53
3Y
113.24
76.60
5Y
113.24
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James Jiayuan Tong
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- DE United States of America 10017
- IPO Date
- Feb 22, 2021
- CIK
- 0001814140
- Similar Companies
- Business
- Brookline Capital Acquisition Corp. was established in 2020 as a special purpose acquisition company, or SPAC. This entity initially sought to identify and merge with one or more businesses through a stock purchase, asset acquisition, recapitalization, or other similar transaction. The company’s strategic focus was primarily on opportunities within the vibrant life sciences sector. Headquartered in New York, New York, Brookline Capital Acquisition Corp. completed its business combination on July 29, 2022, with Apexigen, Inc., a clinical-stage biopharmaceutical firm. Following this reverse merger, the company was subsequently renamed Apexigen, Inc., and its shares began trading on Nasdaq under the new ticker symbol "APGN" as of August 1, 2022.